A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and the safety of dasatinib in subject
with chronic phase chronic myeloid leukemia(CML) who are either resistant to or intolerant of
imatinib mesylate.
Phase:
Phase 2
Details
Lead Sponsor:
Kanto CML Study Group
Collaborator:
Epidemiological and Clinical Research Information Network